Ultra low molecular weight heparin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Editors-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]] '''Associate Editor-In-Chief''': [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org] | '''Editors-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]] '''Associate Editor-In-Chief''': [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org] | ||
==Overview== | ==Overview== | ||
AVE5026 is a hemisynthetic, ultra low molecular weight heparin. It is obtained by highly selective and controlled depolymerization of heparin. It has an average molecular weight of 2000 to 3000 Da, as compared to 4000 to 5000 Da of other LMW heparins. | AVE5026 is a hemisynthetic, ultra low molecular weight heparin. It is obtained by highly selective and controlled depolymerization of heparin. It has an average molecular weight of 2000 to 3000 Da, as compared to 4000 to 5000 Da of other LMW heparins. | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Anticoagulants]] | |||
Revision as of 18:14, 8 September 2011
Editors-in-Chief: C. Michael Gibson, M.S., M.D. Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [1]
Overview
AVE5026 is a hemisynthetic, ultra low molecular weight heparin. It is obtained by highly selective and controlled depolymerization of heparin. It has an average molecular weight of 2000 to 3000 Da, as compared to 4000 to 5000 Da of other LMW heparins.